Phase III Medical Inc. (PHSM.OB) Announces Successful In Vitro Studies And Plans To Begin Animal Studies In Bioshielding Platform Technology Program
10/19/2005 5:08:55 PM
Phase III Medical, Inc. (OTCBB:PHSM) today announced that its collaboration partner, Parallel Solutions, Inc.(PSI), has successfully conducted in vitro evaluation studies of its core library of polyphosphazene polymers and is now ready to begin in vivo animal studies. PSI is conducting a Proof of Concept Study for the development of a new bioshielding platform technology for the delivery of therapeutic proteins. In connection with this study, PSI conducted assays designed to evaluate, for the study protein, protein-polymer complexation, the activity of protein-polymer formulations and their resistance to proteolytic degradation. Based on the encouraging results of these studies, polymers are selected for further evaluation in vivo. Further in vitro studies are ongoing and in vivo animal studies are expected to begin shortly.